CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

Press/Media

Period27 Apr 2020 → 28 Apr 2020

Media coverage

2

Media coverage

  • Title-CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date28/04/20
    PersonsJohn Mascarenhas
  • TitleCTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date27/04/20
    PersonsJohn Mascarenhas
View all 2
View less